Out Of The Pipeline

Ramelteon

Author and Disclosure Information

Hypnotic agent targets delayed sleep onset.


 

References

In clinical trials, ramelteon has helped patients fall asleep more quickly. Whereas other sleep-promoting medications sedate through effects on gamma-butyric acid (GABA) receptors, ramelteon interacts with melatonin receptors to regulate sleep patterns. It is FDA-approved for treating insomnia characterized by sleep-onset difficulty (Table 1)

Table 1

Ramelteon: Fast facts

Brand name:
Rozerem
Class:
Nonbenzodiazepine hypnotic
FDA-approved indication:
Insomnia characterized by sleep-onset difficulty
Approval date:
August 18, 2005
Manufacturer:
Takeda Pharmaceuticals North America
Dosing form:
8-mg tablets
Recommended dosage:
8 mg within 30 minutes of going to bed
Additional prescribing information:
www.rozerem.com

How it works

Ramelteon, a melatonin receptor agonist, has high affinity for the MT1 and MT2 (melatonin) receptors. Although the precise mechanism by which ramelteon affects sleep remains unknown, its effect on sleep is hypothesized to be similar to that of the neurohormone melatonin.

Melatonin is important to maintaining the circadian rhythm that underlies the sleep-wake cycle. Sunlight influences neurohormones that mediate daytime-specific physiologic events. An increase in melatonin—a change that accompanies darkness—is believed to mediate changes in physiology that are characteristic of nighttime. Melatonin thus may be more of a circadian “clock” regulator than a sedative.

Ramelteon shows some features of melatonin that differentiate it from the GABA-related sedating agents. Both ramelteon and melatonin lack abuse potential and a dose-response relationship.

Pharmacokinetics

Ramelteon is absorbed rapidly from the GI tract and reaches median peak concentrations within 30 to 90 minutes of dosing. Taking ramelteon with a high-fat meal reduces its maximum concentration by 22% and slows hypnotic onset by approximately 45 minutes.

The drug is metabolized mostly through the 1A2 isoenzyme of the cytochrome P (CYP)-450 system, although CYP 2C and 3A4 isoenzymes are also involved. About 90% of the dose is excreted.

Ramelteon’s elimination half-life averages 1 to 2.6 hours, so blood levels upon awakening will likely be too low to cause residual effects. Interestingly, in one placebo-controlled study,1 subjects who received a single 64-mg dose reported significantly reduced alertness and diminished ability to concentrate upon awakening. Subjects who took a 16-mg dose did not report this effect. Whether this finding is clinically relevant or relates to a residual effect, sedation, or cognitive impairment is unclear.

Efficacy

In a randomized, double-blind, placebo-controlled trial, ramelteon shortened sleep latency (time between going to bed and falling asleep) among patients with transient insomnia.

Roth et al1 studied 375 healthy adults ages 35 to 60 who reported sleeping 6.5 to 8.5 hours nightly and usually taking ≥30 minutes to fall asleep. In sleep research centers, subjects received one dose of ramelteon, 16 or 64 mg, or placebo 30 minutes before bedtime.

Mean latency to persistent sleep, measured with polysomnography, was 10 minutes shorter among both ramelteon dosage groups than among the placebo group. Mean total sleep time was 11 to 14 minutes longer among both ramelteon groups based on polysomnography, although subjective sleep estimates the next morning were similar among all three groups.

Roth et al2 also assessed efficacy of ramelteon across 5 weeks among 829 older patients (mean age 72) with insomnia (as defined by DSM-IV-TR) for ≥3 months, total nightly sleep time ≤6.5 hours for 3 nights, and self-reported sleep latency ≥45 minutes nightly for ≥3 nights.

Mean sleep latency decreased 25 to 30 minutes among subjects taking ramelteon, 4 or 8 mg nightly, compared with a mean 15-minute decrease among the placebo group. Average total sleep time was 5 to 8 minutes longer among both ramelteon groups compared with placebo.

Subjects in both ramelteon groups then received placebo for 1 week, during which time their mean latency to persistent sleep improved further or stayed the same. This suggests that ramelteon did not cause rebound insomnia.

Safety and tolerability

Ramelteon was generally well tolerated in clinical and preclinical trials. Headaches (7% of subjects), somnolence (5%), dizziness (5%), fatigue (4%), nausea (3%), exacerbated insomnia (3%), and upper respiratory tract infection (3%) were most commonly reported.3 Less-common effects included diarrhea, myalgia, depression, dysgeusia, arthralgia, influenza, and blood cortisol decrease.

The most common side effects among subjects age ≥65 were dizziness, dysgeusia, headaches, myalgia, and somnolence (Table 2). These occurred less frequently over 5 weeks among patients taking 4 mg/d than among those who took 8 mg/d, the FDA-approved dosage.

Ramelteon also showed no abuse potential compared with triazolam and placebo in a trial of 14 patients with a history of anxiolytic or sedative/hypnotic abuse.4


Contraindications

Do not give ramelteon to patients taking fluvoxamine. The antidepressant has been shown to raise serum ramelteon approximately 70-fold, thus substantially increasing the risk of ramelteon-associated adverse events.3

Ramelteon has shown teratogenicity in animals, though at doses far exceeding human levels. Still, as with other sleep-promoting medications, avoid prescribing ramelteon to expectant mothers.

Next Article: